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Introduction 
 
Regenerative medicine holds great promise for restoring the 
normal, healthy functions of human tissues after damage. Its potential 
to treat a broad range of degenerative and ischemic diseases in tissues 
or organs has been improved with significant progress in 
understanding biological mechanisms. Based on current technologies, 
growing tissues and organs in the laboratory becomes a reality in 
regenerative medicine [1]. Tissue engineering is a central tenet of 
regenerative medicine. The purpose of tissue engineering is not only 
to repair damaged organs and tissues, but also to grow healthy ones to 
replace their damaged counterparts in patients [2].  
Currently, engineered biomaterial scaffolds with biological 
functionalization through cell seeding have been widely used to 
regenerate healthy tissues for replacement. Instead of simply 
introducing healthy cells into a diseased region, cells are actually 
seeded onto biomaterial scaffolds before transplantation [3]. These 
biomaterials serve as instructive templates for cell growth and tissue 
architecture so that functional tissue can eventually be formed. 
Therefore, this ultimate outcome can address the urgent issue related 
to available tissue and organs for patients who are awaiting life-saving 
transplantation. Selection of synthetics or natural materials as well as 
appropriate choice of cell type provides numerous options to develop 
various types of tissues and organs. Studies have begun to shed light 
on the significance of nanoscale interactions between cells and 
scaffolds [1, 4]. Recently, a wide range of nanotechnologies for 
material modification has been approached by realizing the fact that 
the extracellular matrix (ECM) consists of nanoscale components and 
exhibits nanoscale architectures. Moreover, cell-cell and cell-ECM 
interactions actively occur on the nanoscale and ultimately play large 
roles in determining cell fate [5]. These cell-ECM interactions are 
based  on  topography,  mechanical  properties  (e.g.  matrix  stiffness,  
  
 
 
 
 
 
 
 
 
  
viscosity and elasticity), concentration gradients of arrested growth 
factors, and ECM molecules. For example, the importance of cell-
ECM interactions was demonstrated by Ott and co-workers [6]. The 
ECM is composed of an intricate interweaving of protein fibers such 
as fibrillar collagen and elastins which range from 10 to hundreds of 
nanometers. This mesh is coated with nanoscale adhesion proteins 
like laminin and fibronection which allow for cell adhesion and cell-
matrix interaction. In this study, rat hearts were decellularized by the 
perfusion of detergents, resulting in preservation of the fundamental 
ECM structure. The researchers observed that collagens I and III, 
laminin, and fibronectin remained within the decellularized heart, 
proving that the integrity of the ECM was kept intact. When the 
decellularized heart was reseeded with cardiac and endothelial cells, 
the cells migrated and self-organized into their natural physiological 
location. By day 8, the cells were even able to generate a pump 
function under both physiological loading and electrical stimulation. 
Similar studies have been conducted for liver [7], bone [8], lung [9], 
and arteries [10]. These works show that for each organ system there 
is a specific environment (e.g., tissue architecture) that helps direct cell 
fate.  
Nanomaterials have provided the potential to preferentially 
control the behavior and differentiation of cells by controlling 
nanoscale properties [4]. With this foundation, the current review is 
focused on the needs of nanotechnology in developing tissue 
engineered scaffolds and the role of nanotechnology in improving 
tissue growth and function or inhibiting abnormal cell proliferation 
for major organs found in both the pulmonary and cardiovascular 
systems.  
 
1. The need of nanotechnology for regenerative medicine  
 
Nanoscale materials and therapeutics have been shown to play 
significant roles in tissue engineering applications since cells respond 
to nanoscale stimuli in spatial parameters [1, 4, 11]. The goal of 
tissue engineering is to build a natural tissue or organ for replacement 
of the damaged body part. This task could be done more effectively, 
if the spatiotemporal profile in expression of key molecules (e.g., 
proteins and polysaccharides) regulating cell behavior can be precisely 
controlled by means of nanotechnology. Although the size of most 
human cells is in the microscale range (10 to 100 µm), biological 
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molecules that play crucial roles in virtually all mechanisms of cell 
function (i.e. adhesion, differentiation and proliferation) are much 
smaller in size.  Specifically, the active sites of adhesion proteins, such 
as those associated with ligand-receptor interactions, cell-cell 
junctions, and cell-ECM binding, are on the order of nanometers. For 
example, the size of fibronectin, a critical protein in cell adhesion and 
proliferation, is approximately 20nm and 10nm in length and width, 
respectively (Fig. 1), and its active site is approximated to be much 
smaller [12]. This means that nanoscale engineering approaches can 
directly influence the response of key molecules in cells and eventually 
change overall cellular behavior, which will ultimately improve tissue-
level functions.   
 
 
 
 
 
 
 
It is truly challenging to engineer ECM proteins and/or 
nanomaterial surfaces to function similar to the natural ECM proteins 
in tissues and organs. However, there have been enormous endeavors 
towards this goal through nanotexturing, nanopatterning and 
nanomaterials, although these techniques still need to be further 
developed [11, 13-15]. 
ECM structure is also important to mimic because it generates the 
level of integrity required for structural support to resident cells, as 
well as regulating a deposition pattern of growth factors [16]. For 
example, collagens are the most abundant proteins in ECM and are 
present as a form of fibrillar proteins. In normal tissues, the anchoring 
fibrils represent tissue structures with nanoscale diameters, but in 
pathological tissue, collagen fibril breakage and abnormal aggregation 
result in disorganized ECM with altered fibril diameters. Therefore, 
well-organized ECM represents the healthy environment, preventing 
cells from being exposed to pathological environments. In order to 
achieve a similar organization via engineering techniques, 
electrospinning can be employed for generating synthetic ECM 
“fibrils” that are structurally similar to those found in normal 
physiology [17, 18].  Moreover, the resulting fibers can be tailored on 
the nanoscale size and functionalized to deliver biological 
components.   
Cells also encounter and interact with many topographical 
features which can range from folded proteins to banded collagen 
[19]. This important interaction can be utilized through surface 
modifications of biomaterial scaffolds. Surface modification can be 
done by nanopatterning different geometries onto the surface of a 
given scaffold [20, 21]. These geometries include nanogrooves, 
nanoposts, and nanopit arrays [19]. The topography of different 
substrates influences a wide range of cellular functions, including 
morphological changes, differentiation, and adhesion.  An example of 
this can be seen when epithelial cells are seeded on surfaces of varying 
topographies. Epithelial cells elongate and align along grooves and 
ridges as small as 70 nm, but the cells are mostly round on smooth 
substrates [22].  
Nanoparticles are also an exciting subject in nanotechnology that 
has been investigated in the field of regenerative medicine. These 
particles are usually loaded with therapeutics and tagged with 
appropriate antibodies. These antibodies are specific to ligands in the 
diseased tissue so the nanoparticles circulate in the body for a long 
period and bind to the desired tissue. A current method of treatment 
is the intravenous injection of therapeutic agents [23-27]. The major 
limitation of this treatment method is the lack of retention in the 
desired target tissue partially due to inefficient targeting. Another 
treatment involves transplantation of biomaterials, thereby enabling 
sustained release of biomolecules, but this involves invasive surgery 
[28-30]. Targeted nanoparticles are more favorable than either of 
these current treatments because of their improved retention and 
minimally invasive administration. There are two primary obstacles 
that must be overcome in order to be a successful targeting vehicle. 
The first obstacle is the delivery vehicle must be transferred across the 
vascular endothelium, which is difficult under normal circumstances. 
A phenomenon known as enhanced permeation and retention (EPR) 
is utilized to ensure the successful transport of nanoparticles across 
the endothelium. This process is primarily seen in tumor vasculature 
that is characterized by the increased endothelial permeability. The 
second obstacle that must be addressed is a molecular target must be 
identified at the desired site of drug action so that a much higher 
concentration of drug can be presented at the site compared to its 
systemic concentration. 
The ECM of each organ in the body differs in their composition 
and spatial organizations [4]. The ECM maintains specific tissue 
morphologies and provides specific instructive cues that are key for 
operating each organ. Therefore, design considerations for scaffolds 
should vary accordingly for each desired organ. The biochemical, 
mechanical and electrical functions of the heart represent the 
importance of this specificity [31]. The three-dimensional ECM 
network of heart is made by intricate, micro and nanoscale 
interweaving of elastin and collagen. In this unique environment, 
cardiomyocytes form elongated and aligned cell bundles as they are 
forced to couple mechanically with each other and to communicate 
electrically through gap junctions. This multi-bundled elongated, 
connected structure is essential for creating the unique electrical and 
mechanical properties of the heart. A specific ECM is also defined for 
the pulmonary system to ensure appropriate diffusion of both carbon 
dioxide and oxygen across the alveolar cell wall. This is essential to 
enable the systemic distribution of oxygen. Many of the current 
therapeutic applications for both the pulmonary and cardiovascular 
system are based on an understanding of nanotechnology. A better 
understanding of these two systems on the nanoscale can lead to novel 
treatments that will advance regenerative medicine. Therefore, the 
following sections will discuss the details of nanotechnology 
approaches for recapitulating tissue- and organ-level functions in 
order to produce significant advances in the field of tissue engineering 
and regenerative medicine. 
Figure 1. Koteliansky et. al. measured length (A) and width (B) of 
fibronectins using electron microscopy. 
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2. Blood vessel 
 
Currently, there are a few conventional strategies used to enhance 
vascularization in tissue-engineered constructs. A favorable way to 
vascularize engineered tissues is to activate the natural angiogenic 
potential of the body [32]; however, the primary disadvantage of this 
approach is that it takes too long for whole implants to become 
properly perfused [33-37]. Instead, nano-structured or nano-surface 
modified vascular scaffolds can be employed to greatly influence cell 
alignment, adhesion and differentiation to promote more efficient and 
complete vascularization. Xu et. al. observed the behavior of smooth 
muscle cells (SMCs) on a biodegradable poly(L-lactide-co-ε-
caprolactone) (75:25) scaffold fabricated to aligned nanoﬁbrous 
structures by electrospinning [35]. When compared to identical 
microscale polymer scaffolds, the electrospun fibers with an aligned 
nonotopography showed improved SMC adhesion, proliferation and 
in vivo-like cell orientation and migration along the aligned 
nanofibers [35]. Tissue engineered vascular grafts have a number of 
requirements that must be met, including appropriate mechanical 
strength, prevention of surface thrombosis, and highly organized 
structures that combine with ECM proteins, such as collagen and 
elastin. For mechanical strength and highly organized structures, 
nanotechnology can be used as a means to create patterning on the 
nanoscale. One recent study developed tubular collagen scaffolds with 
nanopatterns (TNs) to mimic the native vasculature [37].  TNs were 
produced both inside and outside of the tubes, and endothelial cells 
were seeded on the luminal side while smooth muscle cells were 
seeded on the outside of the tubes. Following co-culturing in double-
sided nanopatterned tubes, the phenotypes of both endothelial cell 
and smooth muscle cells were respectively identical to their healthy 
ones. The authors explained that TNs have potential for vascular 
tissue engineering since the TNs enhanced tensile strength while 
improving cell retention in the lumen under blood ﬂow. Additionally, 
both cell types retained their proliferative capacity. Accordingly, 
Figure 2. Zhang et. al. generated a wide range of nanoroughness on PLGA surfaces formed by polystyrene beads. RMS values of A, B, C, D, E and F showed 0.62, 
2.30, 2.33, 5.03, 5.42 and 36.89, respectively. 
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another study showed the importance of strengthening the interaction 
with collagens on the nanoscale to increase mechanical property of 
scaffolds as well as to mimic ECM structure [37].  
One of the largest causes of morbidity and mortality worldwide is 
ischemic tissue diseases. Therapeutic angiogenesis has emerged as a 
potential treatment plan because it enhances microvascular perfusion 
in ischemic tissue by delivering pro-angiogenic molecules. This 
treatment can be optimized through a better understanding of the 
nanoscale regulation of the process that involves both delivering 
growth factors and exerting complex signaling cascades. One of the 
most potent angiogenic factors that have been recognized is vascular 
endothelial growth factor (VEGF). Therefore, many pro-angiogenic 
treatments have attempted to utilize VEGF to enhance 
microvasculature in ischemic tissue. A primary obstacle of the 
treatments with VEGF is inadequate retention of the protein at the 
desired site of action. Webber et al., have developed a supramolecular 
nanostructure that mimics VEGF by reacting with VEGF receptors 
on the cell membrane [38]. This nanomaterial is a liquid that forms a 
matrix of loosely tangled nanofibers when it is injected into a patient. 
The nanofiber is covered in microscopic protuberances that mimic the 
physiological actions of VEGF. These protuberances were able to 
induce VEGF receptor phosphorylation and promote endothelial cells 
to exhibit proangiogenic behavior. When this VEGF-mimetic was 
investigated in a mouse hind-limb ischemia model, the nanostructure 
increased tissue perfusion, functional recovery, limb salvage, and 
treadmill endurance compared to controls. Unfortunately, this 
nanotechnology still does not address the main obstacle of poor 
retention [38].  However, this approach showed an important utility 
of nanotechnology for blood vessel regeneration.     
 
3. Lung 
 
Alterations to surface nanotopography have been employed to 
stimulate a wide range of cell functions. Nanopillars and nanolines 
[34] have been shown to effectively modify the dynamics of cell 
spreading in cancerous fibroblasts. Also the appropriate choice of 
nanoroughness on nanospherical surfaces [36] has been shown to 
adversely affect adhesion and proliferation of lung carcinoma cell 
lines. Both of these nanotechnologies have suggested that cancer cells 
respond to nanoscale changes in surface topography at the polymer 
surface. Zhang et al. have created a wide array of poly(lactic acid-co-
glycolic acid) (PLGA) nanorough surfaces by using 190, 300, 400 
and 530 nm polystyrene nanobeads through PDMS template molds 
(Fig. 2) [36]. The nanoroughness of the surfaces was determined by 
the value of root mean square (RMS) of 2.23, 5.03, 5.42, and 36.90 
nm.  The authors seeded lung carcinoma cells on these surfaces and 
observed the subsequent cell behavior after three days. PLGA surfaces 
with an RMS value of 0.62 nm had the lowest cell density.  The 
contact angle data on each PLGA surfaces exhibited the 
interrelationships between nanotopography and cell adhesion. The 
contact angle value on 0.62 nm rough surface was the lowest at 
approximately 100 degrees while control (glass) indicated the highest 
at approximately 60 degrees [36]. Considering the PLGA surface 
features are on the nanoscale, specific surface nanoroughness may 
inhibit adhesion of lung cancer cells when implanted. This result 
suggests a previously unknown biomaterial cue to inhibit lung cancer 
spreading. 
Nanoparticles (NPs) are another nanotechnology with potential 
for interventional lung cancer treatment.  NP research is currently one 
of the most intensive scientific interests due to a wide range of 
potential applications in the field of regenerative medicine. NPs can 
effectively carry drugs or small molecules in order to modulate 
functions at the cell- and tissue-level, exemplifying how 
nanotechnology can impact physiological function on a much larger 
scale. One recent study investigated the effects of magnetic NPs 
loaded with doxorubicin on lung cancer cell function [39]. The 
authors first synthesized chemically modified superparamagnetic iron 
oxide NPs using N-isopropylacrylamide and methacrylic acid 
(pNIPAAm-MAA) through covalent bonding, and then loaded the 
NPs with doxorubicin for delivery. Based on results from X-ray 
refraction desorption (XRD), the superparamagnetic iron oxide NPs 
ranged from 20-75nm. Following graft polymerization, the NPs 
increased in size to 60-100nm; also the dispersion of particles was 
greatly improved. They found that the pNIPAAm-MAA-grafted NPs 
demonstrated little cytotoxicity to lung cancer cells. Moreover, the 
temperature-dependent property of NIPAAm-MAA allowed grafted 
NPs to preserve the polymer benefits. Thus, doxorubicin-loaded NPs 
showed better drug release efficiency compared to doxorubicin alone 
in 37C. The authors concluded that doxorubicin-loaded NPs could 
be potent inhibitors of lung cancer cells, but further studies are 
needed to confirm how healthy and cancerous cells respond to these 
NPs.  These studies suggest that nanotechnology may contribute to 
the control of cancer cell growth through nanoscale manipulation. 
 
4. Heart 
 
Nanoscale architecture plays a large role in manipulating protein 
adsorption, cell attachment, and  cell functions [5]. When compared 
to plain surfaces, nanofibrous scaffolds have 2.6-3.9 times more 
protein adsorption, including ECM proteins and adhesion molecules 
[5]. Nanomaterials have also been shown to improve cardiomyocyte 
functions.  A recent study reported that the addition of carbon 
nanofibers (CNFs) in PLGA scaffolds promoted cardiomyocyte 
growth and increased both the electrical conductivity and tensile 
strength of the scaffold as compared to conventional polymer 
substrates [40]. These results suggest that the CNFs help provide 
properties similar to those of natural cardiac tissue. The authors 
suggested that the reason for enhanced cardiomyocyte growth upon 
the addition of CNFs may be due to increased wettability of the 
surface, which results in improved adsorption of ECM proteins such 
as fibronectin and vitronectin, on the surface of scaffolds (Fig. 3) 
[15]. Carbon nanotubes (CNTs) have been at the forefront of 
nanotechnology due to their unique electrical, mechanical, and 
thermal properties [4, 41-43]. CNTs have nanostructures with 
cylindrical shape and diameter ranging from 1 to 100 nm. CNTs can 
be functionalized by attaching chemical compounds or drugs for 
delivery [44]. Also once assembled into scaffolds, CNTs can be used 
as constructs for tissue engineering [45]. Recently, when CNT 
platforms were used to culture cardiomyocytes, the growth and 
electrical activity of cultured cardiomyocytes were enhanced. [46]  
The authors created multiwalled CNT platforms by depositing a 
solution of functionalized multiwalled carbon nanotubes onto glass 
coverslips and allowing the solution to dry. Neonatal rat ventricular 
myocytes were then seeded and observed for three days. The 
proliferation of rat cardiomyocytes on CNT platforms was enhanced 
more effectively compared to gelatin-coated substrates and CNT 
platforms with fibroblasts. The cell culture area of rat cardiomyocytes 
on CNT platforms was larger than on the gelatin coated scaffolds, 
which indicates a higher proliferative capacity of cardiomycytes on the 
CNT platforms. Additionally, the metabolic cycles and electrical 
activity (including action potentials) of rat cardiomyocytes on CNTs 
platforms were greatly improved relative to gelatin coated scaffolds 
[46]. These results show that nanotechnology can improve 
regenerative potential of the heart.  
Therapeutic application of nanotechnology 
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When heart tissue is damaged due to a heart attack, cardiac 
patches can be treated for site-specific regeneration. These patches are 
three dimensional porous biomaterial scaffolds seeded with healthy 
cardiomyocytes [28, 47, 48]. A major limitation of these scaffolds is 
their poor conductivity which inhibits cell-cell coupling and delays 
electrical signal propagation [49]. Dvit et. al. incorporated gold 
nanowires into alginate scaffolds which bridged the electrically 
resistant pore walls of alginate and improved electrical coupling 
between neighboring cadiomyocytes [50]. These nanowires are 
synthesized by anisotropic gold seed elongation and have average 
lengths of 1 µm and diameters of 30 nm. When electrically 
stimulated, the cells synchronously contracted and the tissues were 
thicker and better aligned than those grown on pristine alginate. The 
cells grown on these nanowired scaffolds also produced more proteins 
specific to muscle contraction and electrical coupling. This study 
shows that integration of conducting nanowires within three 
dimensional scaffolds increases the potential therapeutic value of 
current cardiac patches.  
As previously stated, the effectiveness of nanoparticles has been 
investigated in inhibiting growth of lung carcinoma cells [36]. 
Nanoparticles have also been investigated in the treatment of damaged 
cardiac tissue. Dvir et al. have developed a nanoparticle that can target 
the infarcted heart [51]. This nanotechnology takes advantage of two 
consequences following a heart attack. Following myocardial 
infarction (MI), the blood vessels in the left ventricle become leaky 
[52]. This result resembles EPR and allows nanoparticle penetration. 
Figure 3. Suggested schematics of nanoroughness effects by Stout et. al. (A) Shows the adsorption of ECM proteins immediately when substrates implanted or 
soaked in media. (B) Indiactes the cardiomyocytes adhered to the substrates and begin to grow. (C) Due to mimicking native myocardium ECM in surface 
features, more cardiomyocytes on nanorough stiff substrates were adhered and grown than on conventional and plain nanorough substrates. 
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The second event utilized following MI is that there is an 
upregulation of angiotensin 1 (AT1) receptors [53], which can serve 
as a specific target identifying unhealthy cardiac tissue. The vehicle 
was a PEGylated liposome with approximately 145 nm in diameter. 
This liposome has the ability to carry a therapeutic payload that can 
be released in a controlled fashion. A peptide that recognizes the AT1 
receptors was covalently attached to the carboxylic groups on the 
PEGylated liposome. This approach exemplifies a successful 
application of nanoparticle in in regenerative medicine based on an 
improved understanding of phenomena on the nanoscale.    
 
Perspective 
 
The field of nanotechnology has witnessed an explosion in 
research efforts over the past decade. Specific advances have been seen 
in nanotechnology applications to biomedicine that have 
revolutionized the way we view disease diagnosis and treatment, and 
tissue regeneration and repair.  Scientists and engineers working 
together within the framework of nanotechnology have worked 
diligently to not only develop and apply their devices and methods 
within their own laboratories but have also sought far-reaching 
interdisciplinary collaborations to identify novel applications for these 
technologies.  Continuous advances in nanotechnology will 
undoubtedly be observed as science and technology progress. 
Maintaining an open dialogue between researchers, clinicians, and 
industry partners is crucial for translatability of these revolutionary 
technologies.  Without question, it is a very exciting time to work in 
the field of nanotechnology toward regenerative medicine as the 
number of researchers expands; the findings and technologies advance 
exponentially; and new avenues for research and application are 
discovered.  Altogether, nanotechnology has provided a new set of 
tools that can help researchers solve current problems involving both 
the pulmonary and cardiovascular systems. However, nanotechnology 
in regenerative medicine is still at an infant level and is a complicated 
interdisciplinary field which needs the collective collaboration of 
physicists, chemists, biologists, engineers, and clinicians. To help 
mature the exciting field of nanotechnology, researchers must unravel 
the mechanisms of cell-biomaterial interactions at the nanoscale and 
develop unique nanotechnology applications in regenerative medicine.  
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